Genetics of Hypercholesterolemia: Comparison Between Familial Hypercholesterolemia and Hypercholesterolemia Nonrelated to LDL Receptor

Jarauta, E. (Universidad de Zaragoza) ; Bea-Sanz, A.M. ; Marco-Benedi, V. ; Lamiquiz-Moneo, I.

Resumen: Severe hypercholesterolemia (HC) is defined as an elevation of total cholesterol (TC) due to the increase in LDL cholesterol (LDL-C) >95th percentile or 190 mg/dl. The high values of LDL-C, especially when it is maintained over time, is considered a risk factor for the development of atherosclerotic cardiovascular disease (ASCVD), mostly expressed as ischemic heart disease (IHD). One of the best characterized forms of severe HC, familial hypercholesterolemia (FH), is caused by the presence of a major variant in one gene (LDLR, APOB, PCSK9, or ApoE), with an autosomal codominant pattern of inheritance, causing an extreme elevation of LDL-C and early IHD. Nevertheless, an important proportion of serious HC cases, denominated polygenic hypercholesterolemia (PH), may be attributed to the small additive effect of a number of single nucleotide variants (SNVs), located along the whole genome. The diagnosis, prevalence, and cardiovascular risk associated with PH has not been fully established at the moment. Cascade screening to detect a specific genetic defect is advised in all first- and second-degree relatives of subjects with FH. Conversely, in the rest of cases of HC, it is only advised to screen high values of LDL-C in first-degree relatives since there is not a consensus for the genetic diagnosis of PH. FH is associated with the highest cardiovascular risk, followed by PH and other forms of HC. Early detection and initiation of high-intensity lipid-lowering treatment is proposed in all subjects with severe HC for the primary prevention of ASCVD, with an objective of LDL-C <100 mg/dl or a decrease of at least 50%. A more aggressive reduction in LDL-C is necessary in HC subjects who associate personal history of ASCVD or other cardiovascular risk factors.

Idioma: Inglés

DOI: 10.3389/fgene.2020.554931

Año: 2020

Publicado en: Frontiers in Genetics 11 (2020), 554931 [13 pp]
ISSN: 1664-8021

Factor impacto JCR: 4.599 (2020)

Categ. JCR: GENETICS & HEREDITY rank: 48 / 175 = 0.274 (2020) - Q2 - T1

Factor impacto SCIMAGO: 1.413 - Genetics (Q2) - Molecular Medicine (Q2) - Genetics (clinical) (Q2)

Financiación: info:eu-repo/grantAgreement/ES/ISCIII/FIS2018-013
Financiación: info:eu-repo/grantAgreement/ES/ISCIII-MSCBS/Juan Rodes program 2018-2021

Tipo y forma: Revisión (Versión definitiva)

Área (Departamento): Area Medicina (Dpto. Medicina, Psiqu. y Derm.)